Page last updated: 2024-12-08
diazipine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
diazipine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 195792 |
| MeSH ID | M0189099 |
Synonyms (10)
| Synonym |
|---|
| diazipine |
| 135330-18-6 |
| 3-o-ethyl 5-o-[2-[[4-[3-(trifluoromethyl)diazirin-3-yl]benzoyl]amino]ethyl] 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate |
| 3,5-pyridinedicarboxylicacid, 1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-, 3-ethyl5-[2-[[4-[3-(trifluoromethyl)-3h-diazirin-3-yl]benzoyl]amino]ethyl] ester |
| DTXSID50928967 |
| ethyl 2-{4-[3-(trifluoromethyl)-3h-diaziren-3-yl]benzamido}ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate |
| 3,5-pyridinedicarboxylicacid,1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-,3-ethyl5-[2-[[4-[3-(trifluoromethyl)-3h-diazirin-3-yl]benzoyl]amino]ethyl]ester |
| cowcyviilyjamo-uhfffaoysa-n |
| 3-ethyl 5-(2-(4-(3-(trifluoromethyl)-3h-diazirin-3-yl)benzamido)ethyl) 2,6-dimethyl-4-(2-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| 3-ethyl 5-[2-({4-[3-(trifluoromethyl)-3h-diazirin-3-yl]phenyl}formamido)ethyl] 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Compound 22 exhibited good pharmacokinetic properties and excellent oral bioavailability (F=78%, rat)." | ( Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy. Banotai, C; Baum, H; Beidler, D; Bove, S; Braden, T; Cornicelli, J; Goodman, A; Gowan, R; Hicks, J; Lightle, S; Lu, XK; Miller, H; Ogden, A; Pandit, J; Plummer, MS; Roark, H; Sadagopan, N; Sanchez, B; Sarver, R; Shahripour, A; Shen, XQ; Skalitzky, DJ; Spessard, C; Stankovic, CJ; Welch, K; Whitehead, C, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 59.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (59.39) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||